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B R I E F  R E P O R T
Late Presentation for Care Among 
Patients With Chronic Hepatitis C: 
Prevalence and Risk Factors
Janne Fuglsang Hansen,1,2 Sofie Hallager,3 Anne Øvrehus,1,2  
Nina Weis,3,4 Peer Brehm Christensen,1,2 and Court Pedersen1,2
1Department of Infectious Diseases, Odense University Hospital, Denmark; 2Clinical Institute, 
University of Southern Denmark, Odense; 3Department of Infectious Diseases, Copenhagen 
University Hospital, Hvidovre, Denmark; 4Faculty of Health and Medical Sciences, Department 
of Clinical Medicine, University of Copenhagen, Denmark 
Patients with chronic hepatitis C may have advanced fibrosis at 
first evaluation. Using the European Association for the Study 
of the Liver (EASL) definition (FibroScan® >9.5 kPa) for “late 
presenter for care” (LP), we found that 32% (169 of 527) of 
patients were LP. Being a LP was associated with increasing age 
and a history of alcohol overuse.
Keywords. chronic hepatitis C; cirrhosis; fibrosis; late pres-
entation; liver stiffness measurement. 
Living with untreated chronic hepatitis C (CHC) may lead to 
liver cirrhosis, consequently increasing the risk of hepatocel-
lular carcinoma (HCC) and hepatic decompensation [1]. New 
treatment regimens with directly acting antivirals (DAAs) cure 
most patients with CHC and reduce the risk of complications, 
especially if treatment is initiated before advanced fibrosis 
occurs [2]. Finding the patients at an earlier stage is crucial to 
achieve the World Health Organization Global Health Sector 
target of reducing liver-related mortality and morbidity by 65% 
by 2030 [3]. Patients with CHC may have been infected many 
years before contact with a treatment facility, and linkage to care 
has been identified as a major obstacle to receiving treatment 
and follow-up for liver disease [4].
A definition of “late presentation” has aided the surveillance 
and identification of risk factors for presenting with advanced 
human immunodeficiency virus (HIV) at the time of diagnosis 
[5]. Therefore, the European Association for the Study of the 
Liver (EASL) and HIV in Europe defined “late presentation 
for care” (LP) of chronic hepatitis to improve the ability to find 
patients before they develop advanced fibrosis and improve sur-
veillance within this group as well. Late presentation for care 
of chronic hepatitis was defined as a liver stiffness measure-
ment (LSM) ≥9.5 kPa, aspartate aminotransferase-to-platelet 
ratio index score >1.5, FIB-4 >3.25, Fibrotest >0.59, or a biopsy 
with Metavir score F3 with no previous antiviral treatment. 
“Presentation with late-stage liver disease” (LSLD) was defined 
as the presence of HCC or decompensated cirrhosis at first con-
sultation [6]. The purpose of this study was to (1) investigate 
the prevalence of LP/LSLD at first consultation at a treatment 
facility in a country with low CHC prevalence and (2) describe 
associated risk factors.
MATERIAL AND METHODS
This study included all adult (age ≥18 years) CHC patients with 
a first consultation for CHC at Odense University Hospital, 
Denmark, from May 2007 to January 2016. Patients were identi-
fied through the Danish Database for Hepatitis B and Hepatitis 
C (DANHEP), a national clinical database including all patients 
with chronic hepatitis B or CHC admitted to hospitals in 
Denmark [7]. Missing information was supplemented with data 
from InfCare, a local quality control database, or extracted from 
patient records. Liver stiffness measurement was extracted from 
the FibroScan device (Echosens, France). Data from the differ-
ent registries were linked using the national, unique 10-digit 
personal identification number.
Late presentation for care was defined as a reliable LSM ≥9.5 
kPa within 180 days of first consultation. Reliability was defined 
as 10 valid measurements and an interquartile range (IQR)/
median <30% if LSM was ≥7.1 kPa [8, 9]. Presenting with LSLD 
was defined as HCC or decompensation within 180 days of ini-
tial consultation.
A history of alcohol overuse was defined as ever having a 
self-reported use above 3/2 units per day (male/female) for 
more than 1 year. A history of intravenous drug use (IDU) was 
defined as ever having a self-reported episode of injecting. The 
project was approved by The Danish Patient Safety Authority 
(j.nr 3-3013-2243/1) and the Danish Data Protection Agency 
(j.nr 2008-58-0035).
Statistical Analysis
Comparison of proportions was done using Pearson’s χ2 test 
and comparison of median values with Kruskal-Wallis test. 
Logistic regression models included age groups, sex, origin 
and history of alcohol overuse, or IDU. There were no statisti-
cal significant interactions. Chronic hepatitis B and HIV were 
excluded in the multivariate models due to small numbers 
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using backward elimination. Goodness of fit was examined 
using the Hosmer and Lemeshow’s method with 6 groups. The 
significance level was set to <0.05. Data were analyzed using 
STATA, version 14.
RESULTS
From May 2007 to January 2016, 570 patients had a first con-
sultation for CHC. Of the 570 patients, 43 (7.5%) did not have 
any data available for evaluation of the degree of fibrosis. These 
patients were a median 4.3 years younger (P < .005) and more 
likely to have a history of alcohol overuse or IDU (P < .005) than 
the included patients.
Late Presentation for Care
There were 169 (32.1%) late presenters for care with no statis-
tically significant change during the 9-year study period. The 
year 2007 had the highest number of first consultations due to 
the implementation of a drug center outreach program. Patients 
with LP were a median of 7 years older than patients with base-
line LSM <9.5 kPa (P < .005). In univariate analysis, age and a 
history of alcohol overuse were strongly associated with LP, and 
this remained significant in multivariable analysis (Table 1).
Presentation With Late Stage Liver Disease
There were 28 (5.3%) patients presenting with LSLD (28 of 169 
of the LP patients). Their median LSM was 51.4 kPa (IQR, 25.8–
69.1) and median age was 50.9  years (IQR, 45.7–56.1). None 
of the LSLD patients were under 30  years of age. Among the 
patients above 30 years of age, a history of IDU was significantly 
associated with reduced risk of presenting with LSLD (Table 1).
DISCUSSION
In this single-center study including CHC patients in Denmark 
presenting to specialized care for the first time, we found that 
32.1% were LP and 5.3% presented with LSLD. Late presenta-
tion for care was associated with increasing age and having a 
history of alcohol overuse. The exclusion of 43 patients with 
missing LSM that had indicators associated with less severe 
disease (young and a history of IDU) could have overestimated 
the proportion of LP, but even if all the excluded patients had 
a LSM <9.5 kPa, the percentage of LP would still be 29.6%. In 
a 5-year follow-up study of CHC, it was shown that LSM >9.5 
kPa was associated with significantly higher mortality [10]. 
This makes the high proportion of LP a significant health 
problem.
A recently published study from New Zealand reported 17%–
22% “late hepatitis notifications”, defined as decompensation or 
HCC before or within 2 years of a reported diagnosis of CHC 
to the health authorities [11]. Compared with our 5% within 
6 months of presentation, their numbers are high. However, the 
results are difficult to compare because we have no informa-
tion on whether the patients in the study had a consultation at 
a treatment facility at the time of diagnosis. The patients in our 
study may have been infected many years previous to their first 
contact with care. The time span from infection to testing and 
from diagnosis and linkage to care is also unknown. Some of the 
delay in our study may have been due to the limited treatment 
options of the past, and with the introduction of the highly ef-
fective DAA treatment, the delay may be reduced the coming 
years. It is also likely that the increased screening in asymptom-
atic patients such as the US baby boomer testing [12] will re-
duce LP in the near future.
Late presentation for care was associated with increasing age 
and alcohol overuse, factors that previously have been linked 
to a high risk of cirrhosis [13, 14]. In our setting, drug users in 
treatment (opiate substitution therapy) have in the past decade 
been targeted for hepatitis C virus screening and evaluation for 
Table 1. Odds Ratios for Late Presentation for Care and for Having Late-Stage Liver Disease at Initial Consultation
Baseline predictor
Model for Late Presentation for Care Model for Presenting With Late-Stage Liver Disease
Univariate OR  
|(95% CI) P Value
Multivariate OR 
(95% CI) P Value
Univariate OR 
(95% CI) P Value
Multivariate OR 
(95% CI) P Value
Western European 0.9 (0.5–1.6) .814 0.8 (0.4–1.5) .549 0.6 (0.2–1.7) .384 0.8 (0.2–2.6) .704
Male sex 1.3 (0.9–1.9) .211 1.4 (0.9–2.1) .171 1.2 (0.5–2.7) .732 1.3 (0.5–3.3) .563
Age (years)
<30 1 N/Aa N/Aa
30–39 3.7 (0.9–16.5) .081 3.8 (0.9–16.8) .080 1 1
40–49 8.9 (2.1–38) .003 8.6 (2–37.2) .005 1.9 (0.6–6.4) .278 1.8 (0.5–5.9) .352
50–59 17.3 (4–74.8) <.005 16.5 (3.8–71.9) <.005 3.8 (1.2–12.1) .024 3 (0.9–9.8) .071
60+ 15.5 (2.9–81.6) .001 14.3 (2.7–77) .002 6.3 (1.3–30.4) .022 4 (0.8–20.9) .099
Hepatitis B coinfection 0.8 (0.3–2) .656 b 2.6 (0.7–9.3) .141 b
HIVb coinfection 2.1 (0.4–10.7) .355 b 3.7 (0.4–32.4) .244 b
History of alcohol use 1.82 (1.2–2.7) .003 1.7 (1.1–2.7) .018 2 (0.8–4.7) .130 2.6 (1–7) .062
History of intravenous drug use 0.8 (0.4–0.9) .275 0.8 (0.4–1.4) .387 0.3 (0.2–0.8) .008 0.3 (0.1–0.8) .016
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio. 
aNo patients in this age group presented with late-stage liver disease.
bCoinfection with hepatitis B and HIV was omitted from the multivariate models due to small numbers with insignificant contribution.
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liver disease. The examinations have been performed in an out-
reach setting making linkage to care easy. This is probably the 
main factor why few patients with IDU were LP in our study.
The association with age was expected but illustrates the 
missed opportunity to diagnose CHC, especially among for-
mer intravenous drug users outside drug treatment centers. 
None of the patients younger than 30 years of age had LSLD, 
probably due to infection in their 20s with less time to develop 
fibrosis. The association of LSLD to not having a history of 
IDU among the patients above 30 years of age may reflect 
the higher number of patients acquiring CHC from other 
sources (primarily nosocomial transmission) in the 1970s and 
1980s before hepatitis C screening of blood products were 
introduced.
CONCLUSIONS
Because a history of IDU accounts for the majority of the 
Danish CHC population [15], testing for CHC in the popula-
tion with a former or present IDU remains the most important 
initiative for earlier diagnosis and timely treatment. However, 
our data also suggest that screening for CHC and liver disease 
among persons born before 1970 or with an overuse of alcohol 
may reduce the risk of LP and presenting with LSLD.
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